Back to search results

MRE Scan for Glioma Patients

This study is looking at a special type of MRI called Magnetic Resonance Elastography (MRE) to see if it can tell the difference between tissue that has been damaged by radiation (radiation necrosis) and a tumor that has grown back (recurrent glioma) in patients who have previously been treated for glioma. You would undergo an MRE and a standard MRI. The main goal is to measure how stiff these different tissues are. This information could help doctors make more accurate diagnoses and better understand how well treatments are working. The study plans to enroll 80 adults aged 18 or older who have a confirmed glioma that was treated with chemotherapy and radiation, and who have a lesion larger than 2 cm.

Study design
This interventional study plans to enroll 80 participants. It is not specified if it is randomized or blinded.
What's involved
You would undergo an MRE scan for 10 minutes and a standard MRI at the beginning of the study. You may also have a biopsy and additional MRI scans within 4 weeks, or 4-8 weeks if no biopsy is performed.
Compensation
Not stated in the trial record.
Follow-up
You will have follow-up MRI scans within 4-8 weeks after the initial MRE scan, depending on whether a biopsy is performed.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04373720

MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas

Recruiting
NAAges 18+InterventionalDiagnostic
M.D. Anderson Cancer Center
~80 participants
Updated 2026-03-05 on ClinicalTrials.gov
What's tested:Magnetic Resonance ElastographyMagnetic Resonance Imaging

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean lesion stiffness
Measured over At baseline

Conditions

Glioma

Explore related trials

Glioma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Melissa Chen, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Melissa Chen, MD
[email protected]
713-745-9789
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

\>/=18 years old.
History of a pathology proven intracranial glioma (including IDH mutant, IDH wildtype or 1p19q co-deleted tumors) treated with chemotherapy and radiation.
The lesion of concern (T2 Flair Hyperintense or contrast enhancing lesion) is \> 2 cm
Patient is able to understand and give consent to participation in the study.

Exclusion

Patients less than 18 years of age.
Pregnant.
Known allergy to gadolinium-based contrast agents.
Renal failure as evidenced by a glomerular filtration rate (GFR) of less than 30 mL/min/1.73m2.
Pacemakers, electronic stimulation, metallic foreign bodies and devices and/or other conditions that are not MR safe, which include but are not limited to:
electronically, magnetically, and mechanically activated implants
ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators and cardiac pacemakers
metallic splinters in the eye
ferromagnetic hemostatic clips in the central nervous system (CNS) or body
cochlear implants
other pacemakers, e.g., for the carotid sinus
insulin pumps and nerve stimulators
non-MR safe lead wires
prosthetic heart valves (if dehiscence is suspected)
non-ferromagnetic stapedial implants
claustrophobia that does not readily respond to oral medication

What this trial measures

  • Mean lesion stiffnessAt baseline

    For each patient, a lesion region of interest (ROI) will be created along with its normal appearing contralateral white matter. The stiffness of the tumor ROI and the contralateral white matter ROI will be measured, and the ratios of the stiffness between the two will be calculated. Interval estimates will be computed for mean stiffness ratio in patients with radiation necrosis or glioma recurrence, separately using a 2-sided 95% confidence interval. Outcome variable of stiffness will be assessed between tumor and contralateral white matter with paired t-tests or Wilcoxon signed-rank tests. The Wilcoxon rank-sum test or t-tests will be used to assess the associations between the outcome variable of stiffness ratio and tumor status (recurrence/necrosis).